Method Validation by Phase of Development: An Acceptable Analytical Practice

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.